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Background
HIV-1 RNA quantification underpins the monitoring of
virological response to antiviral therapy, achievement of
viral suppression and early identification of viral escape.
Most laboratories use commercial HIV-1 RNA viral load
tests and the genetic diversity of HIV-1 requires that these
are applicable across all subtypes. We introduced the
Roche Cobas Ampliprep/Cobas Taqman (CAP/CTM) Real
Time Quantitative HIV-1 RNA PCR into diagnostic service
after conducting a favourable comparative evaluation of
191 samples with the Roche Cobas Amplicor v1.5 PCR
assay [1]. However, concerns were raised when in subse-
quent routine use we identified 10 patients where there
was significant under-quantification (details will be pre-
sented, five subtyped all non-B). A separate study reported
that Roche CTM was under-quantifying a significant
number of samples across a range of subtypes compared
to Amplicor [2]. We have undertaken a larger evaluation
of CAP/CTM versus Roche Amplicor and have included
evaluation of a subset against the Abbott quantitative
HIV-1 RNA real-time PCR test.
Methods
Blood samples were obtained from three HIV clinics in
north-east London for viral load testing. HIV subtype was
obtained either by HIV resistance testing or PCR and
sequence analysis of env and gag regions.
Summary of results
435 plasma samples from 428 patients were tested by
both the CAP/CTM and Amplicor HIV-1 tests. Abbott
HIV-1 real-time PCR was used to determine viral loads in
93 samples. HIV subtype was obtained for 293 samples:
67% were non-B, reflecting the diverse demographics of
the HIV-infected population in east London. There was a
good correlation (R2 = 0.81) between the CAP/CTM and
Amplicor, although this correlation was poorer with CAP/
CTM HIV-1 RNA loads <1000 copies/ml. There was no
apparent difference in the correlation between CAP/CTM
and Amplicor for subtype B and non-B viruses. We identi-
fied one patient with significant under-quantification
(CAP/CTM undetectable compared to Roche Amplicor
and Abbott real-time PCR values of 2.99 and 2.53 log10/
ml, respectively, subtype CRF13_cpx).
Conclusion
Our extended evaluation did not find the significant levels
of under-quantification reported previously [2], although
we did identify a further individual where the present
CAP/CTM test is unsuitable for virological monitoring.
This frequency of significant under-quantification is con-
sistent with our findings in routine diagnostic service and
clinicians should remain alert to the possibility of under-
quantification with this test.
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